Santen Pharmaceutical Co., Ltd.

7 in Phase 3

Quick facts

Founded	1890

DE-108 · Ophthalmology
DE-108 is a small molecule that inhibits Rho-associated protein kinase (ROCK) to reduce intraocular pressure by decreasing aqueous humor outflow resistance.
DE-111 ophthalmic solution · Ophthalmology
DE-111 is a selective dopamine D1 receptor agonist that enhances aqueous humor outflow to reduce intraocular pressure in glaucoma.
DE-114 ophthalmic solution · Ophthalmology
DE-114 is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.
DE-117B Eye Drops · Ophthalmology
DE-117B is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.
STN1012600 ophthalmic solution 0.002% · Ophthalmology
STN1012600 ophthalmic solution 0.002% is a corticosteroid used to reduce inflammation in the eye.
STN1013800 ophthalmic solution · Ophthalmology
STN1013800 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.
Tafluprost ophthalmic solution 0.0015% · Ophthalmology
Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow.

DE-089 ophthalmic solution · Ophthalmology
DE-089 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.
DE-104 ophthalmic solution · Ophthalmology
DE-104 ophthalmic solution is an anti-inflammatory agent that reduces inflammation in the eye.
DE-117 ophthalmic solution high · Ophthalmology
DE-117 ophthalmic solution high is an anti-inflammatory agent.
DE-117 ophthalmic solution low
DE-127 Ophthalmic Solution high dose
DE-127 Ophthalmic Solution low dose
DE-127 Ophthalmic Solution medium dose

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: